Development of new active pharmaceutical ingredients (APIs) is lengthy and cost-intensive, thus avoiding any potential risk that may limit the product’s success is of utmost importance. Today, many APIs are not being commercialized as they are poorly water soluble and, as a result, exhibit too low bioavailability.
The Developability Classification System was developed to assist formulation scientists by introducing two new compound categories: Dissolution rate limited (DCS IIa) and solubility limited (DCS IIb). Depending on where your API lies, there are various strategies to optimize formulation of poorly soluble molecules - From particle size reduction, to solid state modification, to API processing techniques like salt and cocrystal formation.
In this webinar, you will learn:
- About the Developability Classification System (DCS)
- Why it is important to distinguish between dissolution and solubility limited molecules
- Recomended strategies for dissolution enhancement of DCS Class IIa compounds and solubility enhancement of DCS Class IIb compounds
Speakers
Thomas Briel, Ph.D.
Merck
Strategic Marketing Manager, Excipients Liquid Application
Thomas Briel is strategic marketing manager at Merck and responsible for a broad portfolio of excipients for liquid formulation. He has more than 6 years of experience in the pharma and biopharma industry with different positions in the field of pharmaceutical formulation. Thomas holds a Ph.D. in biology from the Technical University of Munich. In parallel to his Ph.D. and industry roles, Thomas acquired a B.S. in economics with a focus on marketing.
Markus Lubda, Ph.D.
Merck
Strategic Business Manager
Markus is a biomolecular engineer. He is responsible for the strategic development and positioning of an excipient portfolio for oral solid dosage form applications. Thereby, the focus is to enhance solubility and bioavailability of the most challenging APIs with specifically engineered excipients for oral solid application. He holds a Ph.D. in biology/chemistry from the Technical University of Darmstadt and is a biomolecular engineer.
Pharma and biopharma manufacturing
- Pharma and biopharma manufacturing
期间:1h 34min
语言:English
场次 1:往期 April 4, 2023
如要继续阅读，请登录或创建帐户。
暂无帐户？